Peanut Component-Specific IgE and IgG4 Are Modulated by Sublingual Immunotherapy and Are Associated With Remission in 1-4-Year-Old Children

Further Publications Immunology

Component-Resolved IgE and IgG4 Profiling Reveals Robust IgG4 Responses Primarily to Abundant Hymenoptera Allergens During Venom Immunotherapy and in Beekeepers

J Investig Allergol Clin Immunol

Blank S, Dorn B, Seiringer P, Grosch J, Slusarenko BO, Dittmar M, Kaczmarcyk R, Rogner D, Jung A, Plail L, Eberlein B, Biedermann T, Darsow U, Brockow K, Schmidt-Weber CB, Jakob T

doi: 10.18176/jiaci.1072

Immunotherapy

Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)

J Allergy Clin Immunol Pract

Pongracic JA, Gagnon R, Sussman G, Siri D, Oriel RC, Brown-Whitehorn TF, Anvari S, Berger WE, Bird JA, Chan ES, Chinthrajah RS, Chong HJ, Fineman SM, Fleischer DM, Gonzalez-Reyes E, Kim EH, Lanser BJ, MacGinnitie A, Mehta H, Petroni D, Rupp N, Schneider LC, Scurlock AM, Sher LD, Shreffler WG, Sindher SB, Wood R, Yang WH, Sampson HA, Bois T, Green TD, Campbell DE, Bee KJ, Bégin P

doi: 10.1016/j.jaip.2025.02.024

Immunotherapy

Sex assigned at birth may modify health-related quality of life in children treated with peanut oral immunotherapy

Pediatr Allergy Immunol

Rosser SA, Lloyd M, Loke P, Ashley S, O'Sullivan MD, Quinn P, Gold M, Tang MLK

doi: 10.1111/pai.70177

Osteoarthritis

Association between socioeconomic status and patient-reported outcome at 1 year after shoulder arthroplasty for osteoarthritis or cuff-tear arthropathy: a nationwide cohort study of 2,292 arthroplasties

Acta Orthop

Jensen ML, Valsamis EM, Madrid AS, Olsen BS, Rasmussen JV

doi: 10.2340/17453674.2024.42700

Atopic Dermatitis

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

J Am Acad Dermatol

Bissonnette R, Gold LS, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI

doi: 10.1016/j.jaad.2025.05.1391

Systemic Lupus Erythematosus

Systemic lupus erythematosus-disease activity score remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in systemic lupus erythematosus remission and lupus low disease activity state

Rheumatology (Oxford)

Nakanishi E, Matsushita M, Minowa K, Tada K, Kawamoto T, Kusaoi M, Amano H, Kon T, Morimoto S, Ikeda K, Suzuki S, Nozawa K, Yang KS, Matsudaira R, Katagiri A, Tsushima H, Urasaki W, Nojiri S, Yamaji K, Tamura N

doi: 10.1093/rheumatology/keaf349

Allergic Diseases

The prevalence of peanut-triggered food protein-induced enterocolitis syndrome in a prospective cohort of infants introducing peanut in the first year of life

Pediatr Allergy Immunol

Verhoeven DHJ, Hofstra G, Faber J, Aalst OB, Breukels M, Hendriks T, van Wijk RG, de Groot H

doi: 10.1111/pai.70058

Immunotherapy

Dosing Reactions and Missed Doses Affect Peanut Oral Immunotherapy Outcomes

J Allergy Clin Immunol Pract

Olayiwola O, Mudd L, Dunaway L, Laidlaw TM, Jones SM, Fulkerson PC, Sanda S, Huffaker MF

doi: 10.1016/j.jaip.2025.11.008

Allergic Diseases

Impact of participant baseline factors on exposure-adjusted incidence of treatment-related adverse events during peanut oral immunotherapy

J Allergy Clin Immunol Pract

Lloyd M, Ashley S, Chawla SS, Loke P, Orsini F, Lozinsky AC, Tang P, Tang MLK

doi: 10.1016/j.jaip.2025.09.010

Related content

Component-Resolved IgE and IgG4 Profiling Reveals Robust IgG4 Responses Primarily to Abundant Hymenoptera Allergens During Venom Immunotherapy and in Beekeepers

Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)

Sex assigned at birth may modify health-related quality of life in children treated with peanut oral immunotherapy

Association between socioeconomic status and patient-reported outcome at 1 year after shoulder arthroplasty for osteoarthritis or cuff-tear arthropathy: a nationwide cohort study of 2,292 arthroplasties

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Systemic lupus erythematosus-disease activity score remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in systemic lupus erythematosus remission and lupus low disease activity state

The prevalence of peanut-triggered food protein-induced enterocolitis syndrome in a prospective cohort of infants introducing peanut in the first year of life

Dosing Reactions and Missed Doses Affect Peanut Oral Immunotherapy Outcomes

Impact of participant baseline factors on exposure-adjusted incidence of treatment-related adverse events during peanut oral immunotherapy